E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy

Frontiers in Bioscience - Landmark

Volumn 20, Issue 3, 2015, Pages 474-490

  Hao, Zhonglin ^a   Huang, Shuang ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cancer therapy; E3 ubiquitin ligase; Inhibitor; Oncogenesis; Review; Skp2

Indexed keywords

ANTINEOPLASTIC AGENT; S PHASE KINASE ASSOCIATED PROTEIN;

CARCINOGENESIS; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASMS; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CARCINOGENESIS; HUMANS; NEOPLASMS; S-PHASE KINASE-ASSOCIATED PROTEINS; UBIQUITINATION;

EID: 84918822949     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4320     Document Type: Review

References (135)

1. A. Hershko, A. Ciechanover, A. Varshavsky: Basic Medical Research Award. The ubiquitin system. Nat Med 6, 1073-1081 (2000) DOI: 10.1038/80384
2. Z. Hao, H. Zhang, J. Cowell: Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol 33, 723-730 (2012) DOI: 10.1007/s13277-011-0291-1
3. M. Scheffner, U. Nuber, J.M. Huibregtse: Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373, 81-83 (1995) DOI: 10.1038/373081a0
4. A. Hershko, A. Ciechanover: The ubiquitin system. Annu Rev Biochem 67, 425-479 (1998) DOI: 10.1146/annurev.biochem.67.1.425
5. J.M. Peters: SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. Curr Opin Cell Biol. 10, 759-768 (1998) DOI: 10.1016/S0955-0674(98)80119-1
6. C. Bai, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274 (1996) DOI: 10.1016/S0092-8674(00)80098-7
7. T. Cardozo, M. Pagano: The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 5,739-751 (2004) DOI: 10.1038/nrm1471
8. H. Zhang, p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 82, 915-925 (1995) DOI: 10.1016/0092-8674(95)90271-6
9. D.J. Demetrick, H. Zhang, D.H. Beach: Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 73, 104-107 (1996) DOI: 10.1159/000134318
10. R.M. Feldman, Correll CC, Kaplan KB, Deshaies RJ: A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91, 221-30 (1997) DOI: 10.1016/S0092-8674(00)80404-3
11. D. Skowyra, Craig KL, Tyers M, Elledge SJ, Harper JW: F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91, 209-219. (1997) DOI: 10.1016/S0092-8674(00)80403-1
12. J. Lisztwan, Marti A, Sutterlüty H, Gstaiger M, Wirbelauer C, Krek W: Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J 17, 368-383 (1998) DOI: 10.1093/emboj/17.2.368
13. C. H. Yam, Ng RW, Siu WY, Lau AW, Poon RY: Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol Cell Biol 19, 635-645 (1999)
14. D. Hanahan, R.A. Weinberg: Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011) DOI: 10.1016/j.cell.2011.02.013
15. V. Esposito, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57, 3381-3385 (1997)
16. M. Loda, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3, 231-234 (1997) DOI: 10.1038/nm0297-231
17. P.S. Steeg, J.S. Abrams: Cancer prognostics: past, present and p27. Nat Med. 3, 152-154 (1997) DOI: 10.1038/nm0297-152
18. A.C. Carrano, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1, 193-199 (1999) DOI: 10.1038/12013
19. H. Sutterluty, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1, 207-214 (1999) DOI: 10.1038/12027
20. L.M. Tsvetkov, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 9, 661-664 (1999) DOI: 10.1016/S0960-9822(99)80290-5
21. K Nakayama, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Nakayama K, Hatakeyama S. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 19, 2069-2081 (2000) DOI: 10.1093/emboj/19.9.2069
22. D. Frescas, M. Pagano: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8, 438-449 (2008) DOI: 10.1038/nrc2396
23. J. Mendez, Zou-Yang XH, Kim SY, Hidaka M, Tansey WP, Stillman B. Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol Cell 9, 481-491 (2002) DOI: 10.1016/S1097-2765(02)00467-7
24. H. Nishitani, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C, Tsurimoto T, Nakayama KI, Nakayama K, Fujita M, Lygerou Z, Nishimoto T. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 25, 1126-1136 (2006) DOI: 10.1038/sj.emboj.7601002
25. R. Hu, A.E. Aplin: Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell 19, 4602-4610 (2008) DOI: 10.1091/mbc.E07-11-1137
26. L. Zhang, Reynolds TL, Shan X, Desiderio S. Coupling of V(D)J recombination to the cell cycle suppresses genomic instability and lymphoid tumorigenesis. Immunity 34, 163-174 (2011) DOI: 10.1016/j.immuni.2011.02.003
27. M. Gellert: V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem 71,101-132 (2002) DOI: 10.1146/annurev.biochem.71.090501.150203
28. P. Mombaerts, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877 (1992) DOI: 10.1016/0092-8674(92)90030-G
29. Y. Shinkai, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992) DOI: 10.1016/0092-8674(92)90029-C
30. H. Jiang, Chang FC, Ross AE, Lee J, Nakayama K, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell 18, 699-709 (2005) DOI: 10.1016/j.molcel.2005.05.011
31. R.K. Slany: The molecular biology of mixed lineage leukemia. Haematologica 94, 984-993 (2009) DOI: 10.3324/haematol.2008.002436
32. S. Takeda, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev 20, 2397-409 (2006) DOI: 10.1101/gad.1449406
33. H. Liu, E.H. Cheng, J.J. Hsieh: Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 21, 2385-2398 (2007) DOI: 10.1101/gad.1574507
34. C.V. Dang: MYC on the path to cancer Cell 149, 22-35 (2012) DOI: 10.1016/j.cell.2012.03.003
35. E.V. Prochownik: c-Myc: linking transformation and genomic instability. Curr Mol Med 8, 446-458 (2008) DOI: 10.2174/156652408785747988
36. E. Laurenti, A. Wilson, A. Trumpp: Myc's other life: stem cells and beyond. Curr Opin Cell Biol 21, 844-854 (2009) DOI: 10.1016/j.ceb.2009.09.006
37. N. von der Lehr, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, Söderberg O, Kerppola TK, Larsson LG. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11, 1189-200 (2003) DOI: 10.1016/S1097-2765(03)00193-X
38. H. Huang, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A 102,1649-1654 (2005) DOI: 10.1073/pnas.0406789102
39. E. Dehan, M. Pagano: Skp2, the FoxO1 hunter. Cancer Cell 7, 209-210 (2005) DOI: 10.1016/j.ccr.2005.02.014
40. Y. Liu, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H, Koff A, Nimer SD. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol 26, 3114-3123 (2006) DOI: 10.1128/MCB.26.8.3114-3123.2006
41. S. Mao, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol 19, 3635-3644 (1999)
42. D.J. Park, Vuong PT, de Vos S, Douer D, Koeffler HP Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood. 102, 3727-3736 (2003) DOI: 10.1182/blood-2003-02-0412
43. H.D. Lacorazza, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, Cordon-Cardo C, Mao S, Pandolfi PP, Nimer SD. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17, 437-449 (2002) DOI: 10.1016/S1074-7613(02)00422-3
44. H.D. Lacorazza, Yamada T, Liu Y, Miyata Y, Sivina M, Nunes J, Nimer SD. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell 9, 175-187 (2006) DOI: 10.1016/j.ccr.2006.02.017
45. M. Braig, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 436, 660-665 (2005) DOI: 10.1038/nature03841
46. M. Collado, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005) DOI: 10.1038/436642a
47. A. Ventura, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007) DOI: 10.1038/nature05541
48. Z. Chen, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005) DOI: 10.1038/nature03918
49. H.K. Lin, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379 (2010) DOI: 10.1038/nature08815
50. B.D. Manning, L.C. Cantley, AKT/PKB signaling: navigating downstream Cell, 129, 1261-1274 (2007) DOI: 10.1016/j.cell.2007.06.009
51. W.L. Yang, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 9, 487-497 (2010) DOI: 10.4161/cc.9.3.10508
52. W.L. Yang, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134-1138 (2009) DOI: 10.1126/science.1175065
53. C.H. Chan, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149, 1098-1111 (2012) DOI: 10.1016/j.cell.2012.02.065
54. Y. Kudo, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 61, 7044-7047 (2001)
55. Y. Dong, Sui L, Watanabe Y, Sugimoto K, Tokuda M. S-phase kinase-associated protein 2 expression in laryngeal squamous cell carcinomas and its prognostic implications. Oncol Rep 10, 321-325 (2003)
56. A. Handra-Luca, Ruhin B, Lesty C, Fouret P. P27, SKP2, and extra-cellular signal-related kinase signalling in human salivary gland mucoepidermoid carcinoma. Oral Oncol 42, 1005-1010 (2006) DOI: 10.1016/j.oraloncology.2005.12.022
57. D.G. Carracedo, Astudillo A, Rodrigo JP, Suarez C, Gonzalez MV. Skp2, p27kip1 and EGFR assessment in head and neck squamous cell carcinoma: prognostic implications. Oncol Rep 20, 589-595 (2008)
58. H. Zhao, He X, Pu Z, Wang Q. (Expression of Skp2 and PTEN and its correlation in glottic carcinoma). Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22, 688-691 (2008)
59. S. Yokoi, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 161, 207-216 (2002) DOI: 10.1016/S0002-9440(10)64172-7
60. C.Q. Zhu, Blackhall FH, Pintilie M, Iyengar P, Liu N, Ho J, Chomiak T, Lau D, Winton T, Shepherd FA, Tsao MS. Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res 10, 1984-1991 (2004) DOI: 10.1158/1078-0432.CCR-03-0470
61. A. Osoegawa, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 22, 4165-4173 (2004) DOI: 10.1200/JCO.2004.01.035
62. V.G. Zolota, Tzelepi VN, Leotsinidis M, Zili PE, Panagopoulos ND, Dougenis D, Tsamandas AC, Scopa CD. Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma. J Surg Res 164, 256-265 (2010) DOI: 10.1016/j.jss.2009.03.035
63. S. Signoretti, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110, 633-641. (2002) DOI: 10.1172/JCI0215795
64. H. Sonoda, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M.Significance of skp2 expression in primary breast cancer. Clin Cancer Res 12, 1215-1220 (2006) DOI: 10.1158/1078-0432.CCR-05-1709
65. G. Yang, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8, 3419-3426 (2002)
66. P.L. Nguyen, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol 29, 302-308 (2011) DOI: 10.1016/j.urolonc.2009.03.022
67. Y. Liang, Hou X, Cui Q, Kang TB, Fu JH, Zhang LJ, Luo RZ, He JH, Zeng YX, Yang HX. Skp2 expression unfavorably impacts survival in resectable esophageal squamous cell carcinoma. J Transl Med 10, 73 (2012) DOI: 10.1186/1479-5876-10-73
68. T.A. Masuda, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K, Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62, 3819-3825 (2002)
69. X.M. Ma, Liu Y, Guo JW, Liu JH, Zuo LF. Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J Gastroenterol 11, 6716-6721 (2005)
70. S. Yachida, Sakamoto M, Imaida K, Yokohira M, Saoo K, Okano K, Wakabayashi H, Maeta H, Suzuki Y. p27(Kip1)is overexpressed in very early stages of hepatocarcinogenesis. Cancer Sci 99, 2152-2159 (2008) DOI: 10.1111/j.1349-7006.2008.00923.x
71. E. Shin, Kim SH, Jeong HY, Jang JJ, Lee K. Nuclear expression of S-phase kinase-associated protein 2 predicts poor prognosis of hepatocellular carcinoma. APMIS 120, 349-357 (2012) DOI: 10.1111/j.1600-0463.2011.02838.x
72. M. Shapira, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer, 103, 1336-1346 (2005) DOI: 10.1002/cncr.20917
73. Y.F. Tian, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Shiue YL, Huang HY, Pan HY, Li CF, Chen SH. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumour Biol 34, 1107-1117 (2013) DOI: 10.1007/s13277-013-0652-z
74. Y.H. Min, Cheong JW, Lee MH, Kim JY, Lee ST, Hahn JS, Ko YW. Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin Cancer Res 10, 5123-5130 (2004) DOI: 10.1158/1078-0432.CCR-04-0136
75. R. Seki, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Shimoda K, Okamura T. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol 21, 833-841 (2010) DOI: 10.1093/annonc/mdp481
76. J. Shaughnessy, Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10 Suppl 1, 117-126 (2005) DOI: 10.1080/10245330512331390140
77. F. Zhan, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109, 4995-5001 (2007) DOI: 10.1182/blood-2006-07-038703
78. A.P. Young, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG Jr. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 10, 361-369 (2008) DOI: 10.1038/ncb1699
79. H. Wang, Bauzon F, Ji P, Xu X, Sun D, Locker J, Sellers RS, Nakayama K, Nakayama KI, Cobrinik D, Zhu L. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet 42, 83-88 (2010) DOI: 10.1038/ng.498
80. A.W. Lin, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12, 3008-3019 (1998) DOI: 10.1101/gad.12.19.3008
81. M. Serrano, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997) DOI: 10.1016/S0092-8674(00)81902-9
82. H. Zhao, Bauzon F, Fu H, Lu Z, Cui J, Nakayama K, Nakayama KI, Locker J, Zhu L. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24, 645-659 (2013) DOI: 10.1016/j.ccr.2013.09.021
83. O. Ben-Izhak, Akrish S, Gan S, Nagler RM. Skp2 and salivary cancer. Cancer Biol Ther 8, 153-158 (2009) DOI: 10.4161/cbt.8.2.7114
84. M. Gstaiger, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W.Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 98, 5043-5048 (2001) DOI: 10.1073/pnas.081474898
85. P. Tosco, La Terra Maggiore GM, Forni P, Berrone S, Chiusa L, Garzino-Demo P. Correlation between Skp2 expression and nodal metastasis in stage I and II oral squamous cell carcinomas. Oral Dis 17, 102-108 (2011) DOI: 10.1111/j.1601-0825.2010.01713.x
86. H.M. Xu, Liang Y, Chen Q, Wu QN, Guo YM, Shen GP, Zhang RH, He ZW, Zeng YX, Xie FY, Kang TB.Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer 30, 204-212 (2011) DOI: 10.5732/cjc.010.10403
87. I. Takanami, The prognostic value of overexpression of Skp2 mRNA in nonsmall cell lung cancer. Oncol Rep 13, 727-731 (2005)
88. S. Yokoi, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J. Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am J Pathol 165, 175-180 (2004) DOI: 10.1016/S0002-9440(10)63286-5
89. W.C. Hung, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 288, 156-161 (2010) DOI: 10.1016/j.canlet.2009.06.032
90. F. Jiang, Todd NW, Li R, Zhang H, Fang H, Stass SA. A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila) 3, 1571-1578 (2010) DOI: 10.1158/1940-6207.CAPR-10-0128
91. M. Slotky, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, Hershko DD. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 7, R737-744 (2005) DOI: 10.1186/bcr1278
92. F. Traub, Mengel M, Lück HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 99, 185-191 (2006) DOI: 10.1007/s10549-006-9202-3
93. O. Ben-Izhak, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M, Cohen S, Ciechanover A. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol 170, 241-245 (2003) DOI: 10.1097/01.ju.0000072113.34524.a7
94. X.C. Wang, Tian LL, Tian J, Jiang XY. Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma. Radiat Res 177, 52-58 (2012) DOI: 10.1667/RR2679.1
95. R. Mamillapalli, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 11, 263-267 (2001) DOI: 10.1016/S0960-9822(01)00065-3
96. D.F. Calvisi, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, Simile MM, Bonelli P, Muroni MR, Seddaiu MA, Lim DS, Feo F, Pascale RM. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137, 1816-1826 (2009) DOI: 10.1053/j.gastro.2009.08.005
97. M. Lu, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, Cui X, He S, Shen A. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 15, 679-687 (2009) DOI: 10.1007/s12253-009-9171-z
98. T. Einama, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y, Matsubara O, Hatsuse K. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 32, 376-381 (2006) DOI: 10.1097/01.mpa.0000220862.78248.c4
99. T. Sanada, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci 95, 969-976 (2004) DOI: 10.1111/j.1349-7006.2004.tb03185.x
100. N. Hashimoto, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, Masaki T, Kinoshita H, Tominaga M, Ajiki T, Ku Y, Okabayashi T, Hanazaki K, Hiroi M, Izumi S, Mano S, Okada S, Karasawa Y, Maeba T, Suzuki Y. Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol 16, 395-403 (2009) DOI: 10.1245/s10434-008-0236-0
101. D. Hershko, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, Hershko A. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91, 1745-1751 (2001) DOI: 10.1002/1097-0142 (20010501)91: 9〈1745::AID-CNCR1193〉3.0.CO;2-H
102. J.Q. Li, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T, Kuriyama S, Imaida K. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol 25, 87-95 (2004)
103. K. Shigemasa, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 9, 1756-1763 (2003)
104. L. Sui, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Oncol Rep 15, 765-771 (2006)
105. M. Lu, Zhao Y, Xu F, Wang Y, Xiang J, Chen D. The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med Oncol 29, 3409-3415 (2012) DOI: 10.1007/s12032-012-0275-z
106. S. Lahav-Baratz, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, Ciechanover A, Dirnfeld M. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod 10, 567-72 (2004) DOI: 10.1093/molehr/gah084
107. C. Langner, von Wasielewski R, Ratschek M, Rehak P, Zigeuner R. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch 445, 631-636 (2004) DOI: 10.1007/s00428-004-1121-2
108. Z. Liu, Fu Q, Lv J, Wang F, Ding K. Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study. J Exp Clin Cancer Res 27, 51 (2008) DOI: 10.1186/1756-9966-27-51
109. A.M. Oliveira, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 21, 722-727 (2003) DOI: 10.1200/JCO.2003.05.112
110. H.Y. Huang, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, Hsiung CY. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 12, 487-498 (2006) DOI: 10.1158/1078-0432.CCR-05-1497
111. S.W. Sorbye, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One 7, e47068 (2012) DOI: 10.1371/journal.pone.0047068
112. A. Lv, Li Z, Tian X, Guan X, Zhao M, Dong B, Hao C. SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS One 8, e62951 (2013) DOI: 10.1371/journal.pone.0062951
113. R.M. Penin, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Overexpression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod Pathol 15, 1227-1235 (2002) DOI: 10.1097/01.MP.0000036589.99516.D6
114. R. Seki, Okamura T, Koga H, Yakushiji K, Hashiguchi M, Yoshimoto K, Ogata H, Imamura R, Nakashima Y, Kage M, Ueno T, Sata M. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 73, 230-235 (2003) DOI: 10.1002/ajh.10379
115. R. Chiarle, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 160, 1457-1466 (2002) DOI: 10.1016/S0002-9440(10)62571-0
116. E. Latres, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 98, 2515-2520 (2001) DOI: 10.1073/pnas.041475098
117. M.S. Lim, Adamson A, Lin Z, Perez-Ordonez B, Jordan RC, Tripp S, Perkins SL, Elenitoba-Johnson KS. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 100, 2950-2956 (2002) DOI: 10.1182/blood.V100.8.2950
118. H.Q. Guo, Pu XX, Guo CC, Rao HL, Li HR, Lin TY. The role of Skp2 in extranodal NK/T-cell lymphoma. Chin J Cancer 29, 567-571 (2010) DOI: 10.5732/cjc.009.10645
119. C. Woenckhaus, Maile S, Uffmann S, Bansemir M, Dittberner T, Poetsch M, Giebel J.Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 20, 501-508 (2005)
120. Q. Li, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 31, 633-642 (2004) DOI: 10.1111/j.0303-6987.2004.00243.x
121. D. Schiffer, Cavalla P, Fiano V, Ghimenti C, Piva R. Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett 328, 125-128 (2002) DOI: 10.1016/S0304-3940(02)00483-4
122. K. Saigusa, Hashimoto N, Tsuda H, Yokoi S, Maruno M, Yoshimine T, Aoyagi M, Ohno K, Imoto I, Inazawa J. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci 96, 676-683 (2005) DOI: 10.1111/j.1349-7006.2005.00099.x
123. Q. Chen, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111, 4690-4699 (2008) DOI: 10.1182/blood-2007-09-112904
124. L. Wu, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol 19, 1515-1524 (2012) DOI: 10.1016/j.chembiol.2012.09.015
125. C.H. Chan, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556-568 (2013) DOI: 10.1016/j.cell.2013.06.048
126. D. Ungermannova, Lee J, Zhang G, Dallmann HG, McHenry CS, Liu X. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J Biomol Screen 18, 910-920 (2013) DOI: 10.1177/1087057113485789
127. M.A. Oettinger, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 248, 1517-1523 (1990) DOI: 10.1126/science.2360047
128. D.G. Schatz, M.A. Oettinger, M.S. Schlissel, V(D)J recombination: molecular biology and regulation. Annu Rev Immunol 10, 359-383 (1992) DOI: 10.1146/annurev.iy.10.040192.002043
129. X. Qiu, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, Lv P, Li Z, Sun X, Wu L, Zheng J, Deng Y, Hou C, Tang P, Zhang S, Zhang Y. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res 63, 6488-6495 (2003)
130. D. Pamarthy, Tan M, Wu M, Chen J, Yang D, Wang S, Zhang H, Sun Y. p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway. Cancer Biol Ther 6, 360-366 (2007) DOI: 10.4161/cbt.6.3.3703
131. C. Lengauer, K.W. Kinzler, and B. Vogelstein, Genetic instabilities in human cancers. Nature 396, 643-649 (1998) DOI: 10.1038/25292
132. S. Akli, K. Keyomarsi, Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2(4 Suppl 1), S38-47 (2003)
133. S.J. Freemantle, E. Dmitrovsky, Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) 3, 1513-1518 (2010) DOI: 10.1158/1940-6207.CAPR-10-0297
134. Y., Ma, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104, 4089-4094 (2007) DOI: 10.1073/pnas.0606537104
135. M. Koutsami, Velimezi G, Kotsinas A, Evangelou K, Papavassiliou AG, Kittas C, Gorgoulis VG. Is exclusive Skp2 targeting always beneficial in cancer therapy? Blood 112, 4777-4779 (2008) DOI: 10.1182/blood-2008-06-161802